Axonyx still has hope for failed Alzheimer's drug (Reuters)


Reuters - Axonyx Inc. said on Tuesday a small
group of patients who received a higher dose of an experimental
Alzheimer's drug showed significant benefit in two late-stage
trials, even though the overall trials failed.